



21 September 2012  
EMA/CHMP/539766/2012  
Press Office

## Opinions on safety variations

Adopted at the CHMP meeting of 17-20 September 2012

Name of medicine	INN	Marketing authorisation holder	Scope
Multaq	dronedarone	Sanofi	CHMP opinion recommending to update section 4.3, 4.4 and 4.5 of the SmPC to contraindicate the concomitant use of dronedarone and dabigatran.
Procoralan/ Corlentor	ivabradine	Les Laboratoires Servier	<p>CHMP opinion recommending to update section 4.4 of the SmPC to reinforce an existing warning in patients with congenital QT syndrome or treated with QT prolonging medicinal products, that heart rate reduction, as caused by ivabradine, may exacerbate QT prolongation, which could give rise to severe arrhythmias.</p> <p>In addition section 4.5 has been updated to include information on the co-administration of potassium-depleting diuretics and the risk of hypokalaemia that when associated with bradycardia is a predisposing factor to the onset of</p>

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom

**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8669

**E-mail** [info@ema.europa.eu](mailto:info@ema.europa.eu) **Website** [www.ema.europa.eu](http://www.ema.europa.eu)

An agency of the European Union



Name of medicine	INN	Marketing authorisation holder	Scope
			<p>severe arrhythmias, especially in patients with long QT syndrome, whether congenital or substance-induced.</p> <p>Also information on the ECG prolonged QT interval was introduced in section 4.8 of the SmPC under category <i>uncommon</i> following the evaluation of the frequency of this adverse reaction in several clinical studies.</p>
Rotateq	rotavirus vaccine, live, oral	Sanofi Pasteur MfSD, SNC	CHMP opinion recommending to update sections 4.4 and 4.8 of the SmPC to include information on angioedema and anaphylactic reaction as adverse events.
Telzir	fosamprenavir	ViiV Healthcare UK Limited	CHMP opinion recommending to update sections 4.4 and 4.5 of the SmPC to include information on drug interactions with Hepatitis C virus (HCV) protease inhibitors.
Thymanax/ Valdoxan	agomelatine	Servier	<p>CHMP opinion recommending to update sections 4.2, 4.4 and 4.8 of the SmPC to include information on cases of liver injury, hepatitis and jaundice as well as recommendation to monitor liver enzymes with the dose increase, and discontinue treatment in case of symptoms and signs of potential liver injury occur.</p> <p>Furthermore, three new adverse events, i.e. vomiting, weight increase, weight decrease were included in the section 4.8 of the SmPC, and updates to sections 4.5 to reflect newly observed drug-drug interactions and 4.6 to reflect limited data on pregnancy outcomes were added.</p> <p>The CHMP endorsed a Direct Healthcare Professional Communication (DHPC) informing healthcare professionals of the revised recommendations.</p>
Vfend	voriconazole	Pfizer Ltd.	CHMP opinion recommending to update section 4.8 of the SmPC to include 'periostitis' as adverse event and to include a warning in section 4.4.

Name of medicine	INN	Marketing authorisation holder	Scope
Zometa	zoledronic acid	Novartis Europharm Ltd.	CHMP opinion recommending to update section 4.4 of the SmPC to include a warning on severe cases of hypocalcaemia and information on risk factors for osteonecrosis of the jaw. In addition, section 4.8 of the SmPC has been updated to include interstitial lung disease.
Adenuric	febuxostat	Menarini International Operations Luxembourg S.A. (MIOL)	CHMP opinion recommending to update section 4.8 to add "rhabdomyolysis" and "angioedema" as preferred terms following the assessment of data coming from post-marketing experience. Additionally, sections 4.4 and 4.5 of the SmPC were updated with information regarding the interaction with mercaptopurine/azathioprine and the mechanism of action of febuxostat on xanthine oxidase, as requested by the CHMP. Section 4 of the Package Leaflet was updated accordingly.